Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04652115 · ClinicalTrials.gov registry record · Phase 2
Defibrotide for the Treatment of Severe COVID-19
A Phase 2 study of Covid19, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT04652115 is a Phase 2 study of Covid19 that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 42 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04652115, a Phase 2 study of Covid19, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia.
Conditions Studied
Interventions
- DRUG Defibrotide
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-01-01 |
| Est. Completion | 2025-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04652115
The ClinicalTrials.gov registry entry for NCT04652115 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 1 intervention - of which Defibrotide is the first listed.
NCT04652115 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04652115 about?
NCT04652115 is a clinical study titled "Defibrotide for the Treatment of Severe COVID-19". The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia.
What is the current status of trial NCT04652115?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2021-01-01. Estimated completion is 2025-03-01.
What conditions does trial NCT04652115 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT04652115?
The interventions under investigation include: Defibrotide (DRUG).
Who is sponsoring clinical trial NCT04652115?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04652115 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
RECRUITING · Phase 2
-
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
ACTIVE NOT RECRUITING · Phase 2
-
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
ACTIVE NOT RECRUITING · Phase 2
-
Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.